Clinical Trials
45 trialsNCT06959706 2026-04-16
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05283226 2026-01-23
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Phase 2 Recruiting
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT04050436 2025-01-27
CERPASS
Replimune, Inc.
Phase 2 Active not recruiting
NCT02834611 2024-05-29
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Keystone Nano, Inc
Phase 1 Completed
NCT02867007 2024-04-25
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT00728390 2024-04-22
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Pfizer
Phase 1 Completed
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT04363242 2023-04-12
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
Synermore Biologics Co., Ltd.
Phase 1 Unknown
NCT04033991 2023-04-06
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Pfizer
Completed
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04985825 2022-09-13
I-PACE
Centessa Pharmaceuticals plc
Phase 2 Withdrawn
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02507544 2020-05-21
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx, Inc.
Phase 1 Completed
NCT02529995 2020-02-11
AURAChinaPK
AstraZeneca
Phase 1 Completed
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT02703298 2019-03-28
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
TaiRx, Inc.
Phase 1 Completed
NCT00818441 2019-01-08
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Pfizer
Phase 2 Completed
NCT01207323 2018-05-01
A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors
Genentech, Inc.
Phase 1 Completed
NCT00477425 2017-05-15
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Genentech, Inc.
Withdrawn
NCT02977364 2016-11-30
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT02587819 2016-04-14
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
Biosceptre
Phase 1 Completed
NCT00998192 2016-03-31
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00941863 2016-03-22
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Bayer
Phase 1 Completed
NCT00879684 2015-01-26
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn
NCT00613691 2013-10-21
A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT01320020 2013-07-02
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Neovii Biotech
Phase 1 Terminated
NCT00988741 2013-02-28
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT00822809 2012-10-03
CASIMAS
Neovii Biotech
Phase 3 Completed
NCT00292864 2012-06-07
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Sunesis Pharmaceuticals
Phase 1 Completed
NCT00447005 2012-05-23
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01223209 2012-01-11
A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
Lytix Biopharma AS
Phase 1 Completed
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed
NCT00879554 2010-12-13
CVX-045-101
Pfizer
Phase 1 Completed
NCT00557596 2009-12-01
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
Aegera Therapeutics
Phase 1/2 Terminated
NCT00137423 2009-09-30
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00613652 2009-07-21
A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients
AstraZeneca
Phase 1 Completed
NCT00099190 2009-04-28
ARQ 501 in Combination With Docetaxel in Patients With Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00195299 2007-12-27
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
Wyeth is now a wholly owned subsidiary of Pfizer
Completed